Newry software firm founder undergoing treatment for cancer
First Derivatives founder Brian Conlon has said he will remain at the helm of the software firm despite being diagnosed with cancer.
The Newry-based financial services group, which trades on both the London and Irish stock exchange, informed Dublin's Euronext on Friday morning of the 53-year-old chief executive's recent diagnosis.
Mr Conlon is set to undergo weekly chemotherapy over the course of several months. The company's chairman Seamus Keating has said he will provide additional executive and governance support.
"The board has set a clear strategy and the executive committee, led by Brian, has delivered strong execution of that strategy year-on-year," he said.
"During the period of his treatment I will provide additional executive and governance support and I am confident that Brian and his team will continue to execute the group's growth plans successfully."
Founded by Mr Conlon in 1996, First Derivatives reported sales growth of 20% to £105.6m for the six months ending August 31, 2018. Its clients now include global banks JPMorgan, Lloyds and Morgan Stanley.
Head-quartered in Newry, the company employs around 2,500 across offices in Belfast, Dublin, London and New York. It moved into the Weaving Works on Belfast's Ormeau Avenue in 2017, office capable of housing 320 people.
Please log in or register with belfasttelegraph.co.uk for free access to this article.
The group employs around 600 in Newry, where it has developed new offices. In September, First Derivatives announced plans to create another 1,000 jobs across the organisation over the next three years.
Earlier this year, Brian Conlon was listed among the wealthiest individuals in Northern Ireland.